Guidance

Pertussis vaccination in pregnancy, dTaP/IPV (Boosterix® or Repevax®): PGD template

PGD template to support the national pertussis vaccination for pregnant women immunisation programme.

Document

Diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (dTaP/IPV) for pregnant women: patient group direction (PGD) template

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (eg a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Detail

This patient group direction (PGD) template is to support the administration of low dose diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (dTaP/IPV) by currently registered nurses or midwives. This applies to women from 20 weeks of pregnancy in accordance with the pertussis vaccination for pregnant women national immunisation programme for active immunisation of the pregnant woman and to provide passive immunity in the neonate against pertussis. It is valid from 1 April 2016 to 31 March 2018.

The PGD template requires further authorisation by a clinical governance or patient safety lead, who has designated responsibility for signing PGDs on behalf of NHS England for their geographical area. The PGD is not legal or valid without this local, formal authorisation.

Adoption and governance of the use of this PGD is the responsibility of the authorising commissioning body and providers.

Provider organisations, health professionals and immunisation practitioners should check they are working to the current PGD versions and only work to a legally authorised PGD from their commissioning body.

These PGDs should be used with reference to the Green Book, and Summary of Product Characteristics for the vaccine.